Eli Lilly and Company (LLY · NYSE)
LLY · MARKET VIEW
Market view · as of Jul 27, 2026
Revenue (TTM)
$72.25B
+55.5% YoY
Gross margin
82.8%
EPS (latest q)
$8.55
vs $6.79 est · beat
52-wk position
93.6%
-3.2% vs 52w high · +6.1% 1mo
Price (last ~year)
Eli Lilly and Company (LLY) commands a $1.06 trillion market capitalization, underpinned by a 55.5% year-over-year revenue increase and a 169.9% surge in earnings. The company reported $19.80 billion in revenue and $7.40 billion in net income for the quarter ending March 31, 2026, marking its fourth consecutive earnings beat. With an operating margin of 49.4%, the stock trades at a price-to-earnings ratio of 42.55 and has appreciated 37.1% over the last three months.
Valuation
- Market cap
- $1.06T
- P/E
- 42.55
- PEG
- 1.672
- P/B
- 34.19
- P/S
- 14.87
- EV/EBITDA
- 30.5
- Beta
- 0.506
- Analyst target
- $1270.37
Quality & returns
- Gross margin
- 82.8%
- Operating margin
- 49.4%
- Profit margin
- 35.0%
- ROE
- 107.5%
- ROA
- 20.7%
Price movement
- Last
- $1196.03
- 1-month
- +6.1%
- 3-month
- +37.1%
- RSI (14)
- 49
- vs SMA200
- +18.0%
- 52-wk position
- 93.6% -3.2% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $19.80B | $8.85B | $7.40B | $9.69B |
| 2025-12-31 | $19.29B | $8.78B | $6.64B | $8.39B |
| 2025-09-30 | $17.60B | $8.39B | $5.58B | $7.88B |
| 2025-06-30 | $15.56B | $7.13B | $5.66B | $7.50B |
Recent news
- Somewhat-Bullish Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 · 2026-07-26
- Neutral Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? · 2026-07-26
- Somewhat-Bullish Merck stock trades steadily as oncology revenue supports earnings outlook · 2026-07-26
- Neutral HUTCHMED (China) Ltd (HCM) Earnings Forecast: Future EPS & Revenue Growth Estimates · 2026-07-26
- Somewhat-Bullish CRON|Cronos Group Inc|Price:2.810|Chg%:+0.070 · 2026-07-26
- Somewhat-Bullish AKBA|Akebia Therapeutics Inc|Price:1.220| · 2026-07-26
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)